This study tests an experimental drug called ARX788 in people with HER2-positive breast cancer that has spread and no longer responds to standard treatments. About 72 adults will receive the drug to see if it shrinks tumors and how long that effect lasts. The goal is to find a ne…
Phase: PHASE2 • Sponsor: Ambrx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC